@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAv5jHxwK2unmprYt2T26PZcgdE-obRBSFu3Wj-2g1KsQ> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAv5jHxwK2unmprYt2T26PZcgdE-obRBSFu3Wj-2g1KsQ#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: hgnc:1653;
    a Protein: .
  
  sub:_2 geneProductOf: hgnc:5981;
    a Protein: .
  
  sub:_3 occursIn: obo:CL_0000842, species:9606;
    rdf:object sub:_2;
    rdf:predicate belv:increases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "p(HGNC:CD28) -> p(HGNC:IL17A)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_5;
    pav:version "20131211" .
  
  sub:_4 prov:value "Incubation of PBMCs with 10 microgram/ml anti-CD3 significantly upregulated IL-17 production upto 3.7 fold, and combination of anti-CD3 and anti-CD28 produced more IL-17 (approximately 1.3-1.5 fold) than anti-CD3 alone. Furthermore, treatment with LY294002 and wortmannin, inhibitors of PI3K, and PDTC, NFkB inhibitor markedly blocked the anti-CD3 and anti-CD28 induced IL17 protein and mRNA production in a dose dependent manner. This indicates that CD3 and CD28 induced IL-17 production was mediated by PI3K pathway.";
    prov:wasQuotedFrom pubmed:15642134 .
  
  sub:_5 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:15642134;
    prov:wasDerivedFrom beldoc:, sub:_4 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:32:37.446+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}